Research programme: zinc trisodium pentetate oral - Nanotherapeutics

Drug Profile

Research programme: zinc trisodium pentetate oral - Nanotherapeutics

Alternative Names: NanoDTPA™; NanoDTPA™Zn-DTPA

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nanotherapeutics
  • Developer Nanotherapeutics; National Institute of Allergy and Infectious Diseases
  • Class Acetic acids; Heavy metals; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute radiation syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO, Capsule)
  • 31 Aug 2010 Nanotherapeutics files an IND application with the US FDA for the treatment of Acute radiation syndrome with zinc trisodium pentetate oral
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top